Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

Giuseppe Badalamenti, Lorena Incorvaia, Salvatore Provenzano, Giuseppe Bronte, Gaetano Leto, Fabio Fulfaro, Giuseppa Maltese

Research output: Contribution to journalArticlepeer-review


Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patients receiving three cycles of chemotherapy with epirubicin plus ifosfamide were treated. None developed FN; G4 neutropenia was reported in 17% of patients. No treatment delay or dose reduction was required, no antibiotic therapy was administered and no hospitalization occurred. Conclusion: Five-day lenograstim treatment is efficient as prophylaxis of FN for soft tissue sarcoma chemotherapy regimens and allows maintenance of chemotherapy dose intensity.

Original languageEnglish
Pages (from-to)679-684
Number of pages6
JournalAnticancer Research
Issue number2
Publication statusPublished - Feb 2013


  • Febrile neutropenia
  • G-CSF
  • Lenograstim
  • Soft tissue sarcomas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma'. Together they form a unique fingerprint.

Cite this